Mostrando 10 resultados de: 17
Filtros aplicados
Publisher
Journal of Alzheimer's Disease(3)
Biomedicine and Pharmacotherapy(2)
Ageing Research Reviews(1)
Experimental Gerontology(1)
Frontiers in Aging Neuroscience(1)
Área temáticas
Enfermedades(17)
Farmacología y terapéutica(8)
Fisiología humana(7)
Medicina y salud(7)
Ginecología, obstetricia, pediatría, geriatría(1)
Origen
scopus(17)
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusC-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations
ReviewAbstract: Given the highly multifactorial origin of Alzheimer's disease (AD) neuropathology, disentangling andPalabras claves:Alzheimer's disease, Amyloid-β, axonal transport, hyperphosphorylated tau, JNK, synapse lossAutores:Antoni Camins, Auladell C., Busquets O., Castro-Torres R.D., Ettcheto M., Parcerisas A., Verdaguer E., Zárate C.B.Fuentes:scopusA metabolic perspective of late onset Alzheimer's disease
ReviewAbstract: After decades of research, the molecular neuropathology of Alzheimer's disease (AD)is still one of tPalabras claves:Alzheimer's disease, c-Jun N-terminal kinase inhibitors, Insulin, Licochalcone A, neuroinflammation, Reticulum stress, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E., Zárate C.B.Fuentes:scopusADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
ReviewAbstract: Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-Palabras claves:ADAM10, Alzheimer's disease, Natural compounds, Pharmaceutical, α-SecretaseAutores:Antoni Camins, Busquets O., Cano A., Cominetti M.R., Di Luca M., Endres K., Ettcheto M., Manzine P.R., Marcello E., Olloquequi J., Pelucchi S.Fuentes:scopusDexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways
ArticleAbstract: The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a rePalabras claves:Alzheimer's disease, APPswe/PS1dE9, Dexibuprofen, hippocampus, insulin receptor, Memory impairment, Mitochondria, TauAutores:Antoni Camins, Auladell C., Busquets O., Ettcheto M., Folch J., García M.L., Olloquequi J., Pallás M., Pons L., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusEvaluation of neuropathological effects of a high-fat diet in a presymptomatic Alzheimer's disease stage in APP/PS1 mice
ArticleAbstract: Alzheimer's disease (AD) is currently an incurable aging-related neurodegenerative disorder. RecentPalabras claves:Alzheimer's disease, APPswe/PS1dE9, hippocampus, insulin receptor, Mitochondria, TauAutores:Alva N., Antoni Camins, Auladell C., Carbonell T., Ettcheto M., Folch J., Pallás M., Pedros I., Petrov D., Zárate C.B.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusNew potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9
ArticleAbstract: Dexibuprofen loaded pegylated poly(lactic-co-glycolic) nanospheres prepared by solvent diffusion metPalabras claves:Alzheimer's disease, Blood–Brain barrier, Dexibuprofen, Nanoparticles, Nanospheres, PLGA-PEGAutores:Antoni Camins, Calpena A.C., Egea M.A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusHypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice
ArticleAbstract: Previous studies suggest that Alzheimer's disease (AD) neurobiology could not be explained solely byPalabras claves:Alzheimer's disease, APP/PS1, cholesterol, hippocampus, LDLR-/-, OXPHOSAutores:Alegret M., Antoni Camins, De Lemos M.L., Ettcheto M., Folch J., Laguna J.C., Pallás M., Pedros I., Petrov D.Fuentes:scopusMasitinib for the treatment of alzheimer's disease
ArticleAbstract: The actual standard treatment for mild-to-moderately severe Alzheimer's disease only attacks its symPalabras claves:Alzheimer's disease, clinical trials, masitinib, mechanism of actionAutores:Antoni Camins, Auladell C., Cano A., Ettcheto M., Folch J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus